Pharma BD Deal Intelligence
A quiet vertical-integration win: Beckman Coulter's $185M cash buy of Lumigen locked up the chemiluminescent chemistry supplying its Access immunoassay line, and the franchise it fed grew double-digit for years before Danaher acquired Beckman itself in 2011. Lumigen still operates today with no record of divestiture or impairment.
A quiet, durable vertical-integration bolt-on: Beckman secured its key immunoassay input supplier, and the underlying franchise it fed grew steadily for a decade-plus with no signs of impairment or divestiture.
Full analysis, sources & comparables →Beckman Coulter pays $185M cash for long-time supplier Lumigen, projecting EPS-accretion by 2007 of at least $0.02/share.
Acquisition secures Beckman's chemiluminescent reagent pipeline; Lumigen had been a key Access supplier for over a decade.
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Chemiluminescent diagnostics chemistry; key supplier to Beckman Access immunoassay
A quiet, durable vertical-integration bolt-on: Beckman secured its key immunoassay input supplier, and the underlying franchise it fed grew steadily for a decade-plus with no signs of impairment or divestiture.
Assessment window: 15yr post-close.
$33M Lumigen 2005 revenue
Lumigen developed chemiluminescent detection chemistries used in automated clinical immunoassay analyzers for high-sensitivity testing of hormones, cardiac markers, infectious disease antigens and tumor markers. The detection chemistry is upstream of any specific disease indication and serves the broader in vitro diagnostics market.
The mid-2000s clinical immunoassay market was led by Roche Diagnostics (Elecsys electrochemiluminescence platform), Abbott (Architect), Siemens (Centaur via Bayer Diagnostics acquisition), Ortho-Clinical (J&J) and Beckman Coulter (Access family). Detection chemistry was a strategic chokepoint: Lumigen supplied the chemiluminescent substrate (LumiPhos, APS-5) for Beckman's Access analyzers, with ~40% of Lumigen's $33M 2005 revenue tied to Beckman. The acquisition vertically integrated a critical reagent supplier, eliminated a single-source supply risk, and protected Beckman's immunoassay roadmap against Roche's competing Elecsys ECL chemistry. The deal is best understood as supply-chain insurance and IP capture rather than therapeutic pipeline expansion. Beckman itself was later acquired by Danaher in 2011 for $6.8B, with Lumigen chemistry continuing to underpin the Access immunoassay franchise.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Beckman Coulter Inc. / Lumigen Inc. (this deal) | 2006 | $185M | 69 |
| Beckman Coulter Inc. / Diagnostic Systems Laboratories Corporation (DSL) | 2005 | $138M | — |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Crucell N.V. / Berna Biotech AG | 2006 | $450M | 85 |
| Lonza Group AG / Cambrex Bioproducts and Biopharma businesses | 2006 | $460M | 83 |
| Reckitt Benckiser plc / Boots Healthcare International | 2006 | $3.4B | 82 |
| Genentech, Inc. (Roche Group) / Tanox Inc. | 2006 | $919M | 80 |
← Browse all deals · How we score deals
More: 2006 deals